Pancreatic Cancer Research

Clinical trialPhase 2 / Phase 3Recruiting

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

Cisplatin Based Regimen to Patients With Advanced Pancreatic Cancer and Homologous Recombination Deficiency

NCT06095141↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Ongoing
Phase
Phase 2 / Phase 3
Status
Recruiting
Study type
Interventional
Start
1 December 2023
Expected end
31 October 2026
Enrollment
30 participants
Sites
1
Primary outcomes
progression-free survival, PFS
Sponsor
Other
Results posted
No
Last update
7 August 2025

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 2